vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and BLACKBERRY Ltd (BB). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $141.8M, roughly 1.3× BLACKBERRY Ltd). BLACKBERRY Ltd runs the higher net margin — 9.7% vs -0.7%, a 10.4% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -0.8%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $17.4M). Over the past eight quarters, BLACKBERRY Ltd's revenue compounded faster (17.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
BlackBerry Limited, formerly Research In Motion (RIM), is a Canadian software company specializing in secure communications and the Internet of Things (IoT). Founded in 1984, it developed the BlackBerry brand of two-way pagers, smartphones, and tablets. The company later transitioned to providing software and services and holds critical software application patents.
AVNS vs BB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $141.8M |
| Net Profit | $-1.3M | $13.7M |
| Gross Margin | 47.5% | 77.5% |
| Operating Margin | 1.4% | 8.4% |
| Net Margin | -0.7% | 9.7% |
| Revenue YoY | 0.7% | -0.8% |
| Net Profit YoY | 99.7% | 224.5% |
| EPS (diluted) | $-0.02 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $141.8M | ||
| Q3 25 | $177.8M | $129.6M | ||
| Q2 25 | $175.0M | $121.7M | ||
| Q1 25 | $167.5M | $141.7M | ||
| Q4 24 | $179.6M | $143.6M | ||
| Q3 24 | $170.4M | $126.2M | ||
| Q2 24 | $171.7M | $123.4M | ||
| Q1 24 | $166.1M | $102.1M |
| Q4 25 | $-1.3M | $13.7M | ||
| Q3 25 | $-1.4M | $13.3M | ||
| Q2 25 | $-76.8M | $1.9M | ||
| Q1 25 | $6.6M | $-7.4M | ||
| Q4 24 | $-397.3M | $-10.5M | ||
| Q3 24 | $4.3M | $-19.7M | ||
| Q2 24 | $1.8M | $-41.4M | ||
| Q1 24 | $-900.0K | $-56.2M |
| Q4 25 | 47.5% | 77.5% | ||
| Q3 25 | 48.4% | 74.5% | ||
| Q2 25 | 52.6% | 74.2% | ||
| Q1 25 | 53.6% | 73.5% | ||
| Q4 24 | 54.6% | 78.1% | ||
| Q3 24 | 54.5% | 70.2% | ||
| Q2 24 | 55.7% | 72.9% | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 8.4% | ||
| Q3 25 | 0.1% | 8.9% | ||
| Q2 25 | -42.6% | 1.6% | ||
| Q1 25 | 6.1% | -5.6% | ||
| Q4 24 | -233.0% | 13.6% | ||
| Q3 24 | 7.0% | 1.7% | ||
| Q2 24 | 3.7% | -10.5% | ||
| Q1 24 | 2.4% | 50.0% |
| Q4 25 | -0.7% | 9.7% | ||
| Q3 25 | -0.8% | 10.3% | ||
| Q2 25 | -43.9% | 1.6% | ||
| Q1 25 | 3.9% | -5.2% | ||
| Q4 24 | -221.2% | -7.3% | ||
| Q3 24 | 2.5% | -15.6% | ||
| Q2 24 | 1.0% | -33.5% | ||
| Q1 24 | -0.5% | -55.0% |
| Q4 25 | $-0.02 | $0.02 | ||
| Q3 25 | $-0.03 | $0.02 | ||
| Q2 25 | $-1.66 | $0.00 | ||
| Q1 25 | $0.14 | $-0.01 | ||
| Q4 24 | $-8.64 | $-0.02 | ||
| Q3 24 | $0.09 | $-0.03 | ||
| Q2 24 | $0.04 | $-0.07 | ||
| Q1 24 | $-0.02 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $304.2M |
| Total DebtLower is stronger | $90.3M | $196.2M |
| Stockholders' EquityBook value | $778.2M | $741.1M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | 0.12× | 0.26× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $304.2M | ||
| Q3 25 | $70.5M | $290.5M | ||
| Q2 25 | $90.3M | $306.6M | ||
| Q1 25 | $97.0M | $337.8M | ||
| Q4 24 | $107.7M | $220.0M | ||
| Q3 24 | $89.0M | $211.0M | ||
| Q2 24 | $92.2M | $229.0M | ||
| Q1 24 | $75.8M | $237.1M |
| Q4 25 | $90.3M | $196.2M | ||
| Q3 25 | $93.4M | $195.9M | ||
| Q2 25 | $95.7M | $195.6M | ||
| Q1 25 | $98.0M | $195.3M | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | $194.1M |
| Q4 25 | $778.2M | $741.1M | ||
| Q3 25 | $778.0M | $725.1M | ||
| Q2 25 | $776.3M | $725.1M | ||
| Q1 25 | $839.4M | $719.9M | ||
| Q4 24 | $828.5M | $725.2M | ||
| Q3 24 | $1.2B | $732.1M | ||
| Q2 24 | $1.2B | $742.6M | ||
| Q1 24 | $1.2B | $775.1M |
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $1.7B | $1.3B | ||
| Q2 24 | $1.7B | $1.3B | ||
| Q1 24 | $1.7B | $1.4B |
| Q4 25 | 0.12× | 0.26× | ||
| Q3 25 | 0.12× | 0.27× | ||
| Q2 25 | 0.12× | 0.27× | ||
| Q1 25 | 0.12× | 0.27× | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | 0.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $18.3M |
| Free Cash FlowOCF − Capex | $21.3M | $17.4M |
| FCF MarginFCF / Revenue | 11.8% | 12.3% |
| Capex IntensityCapex / Revenue | 3.8% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $42.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $18.3M | ||
| Q3 25 | $14.0M | $3.9M | ||
| Q2 25 | $6.8M | $-18.0M | ||
| Q1 25 | $25.7M | $41.6M | ||
| Q4 24 | $57.9M | $6.0M | ||
| Q3 24 | $23.0M | $-16.0M | ||
| Q2 24 | $27.8M | $-15.1M | ||
| Q1 24 | $-8.0M | $-15.5M |
| Q4 25 | $21.3M | $17.4M | ||
| Q3 25 | $7.0M | $3.1M | ||
| Q2 25 | $-4.2M | $-18.9M | ||
| Q1 25 | $19.0M | $41.2M | ||
| Q4 24 | $53.1M | $5.2M | ||
| Q3 24 | $20.0M | $-16.5M | ||
| Q2 24 | $21.9M | $-16.5M | ||
| Q1 24 | $-12.1M | $-17.6M |
| Q4 25 | 11.8% | 12.3% | ||
| Q3 25 | 3.9% | 2.4% | ||
| Q2 25 | -2.4% | -15.5% | ||
| Q1 25 | 11.3% | 29.1% | ||
| Q4 24 | 29.6% | 3.6% | ||
| Q3 24 | 11.7% | -13.1% | ||
| Q2 24 | 12.8% | -13.4% | ||
| Q1 24 | -7.3% | -17.2% |
| Q4 25 | 3.8% | 0.6% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | 6.3% | 0.7% | ||
| Q1 25 | 4.0% | 0.3% | ||
| Q4 24 | 2.7% | 0.6% | ||
| Q3 24 | 1.8% | 0.4% | ||
| Q2 24 | 3.4% | 1.1% | ||
| Q1 24 | 2.5% | 2.1% |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | -9.47× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
BB
| QNX | $68.7M | 48% |
| Secure Communication | $67.0M | 47% |
| Licensing | $6.1M | 4% |
